News Release

Take 2: What protein and where it is located are important for drug design

Peer-Reviewed Publication

JCI Journals

Drugs that target a single signaling pathway that drives tumor development and/or progression have been developed successfully to treat a few forms of cancer. However, in many cases drugs designed using this approach have not worked. Dario Altieri and colleagues, at the University of Massachusetts Medical School, Worcester, have now addressed this issue by using a combinatorial approach to drug design.

The authors developed small molecules, which they termed Gamitrinibs, that target Hsp90, a protein that controls the folding of proteins in multiple signaling networks that drive tumor development and progression. In addition to targeting a protein that controls multiple signaling pathways, the authors designed the drugs to target one specific cellular compartment in which Hsp90 is active in tumor cells, mitochondria. Importantly, treatment with these drugs effectively induced tumor cell death in mice transplanted with human tumor cell lines. The authors therefore conclude that combinatorial drug design, whereby inhibitors of signaling networks are targeted to specific cellular compartments, may prove a more effective strategy for developing anticancer drugs than targeting single signaling pathways. In an accompanying commentary, Nesrin Özören and colleagues, at Bogaziçi University, Turkey, highlight the novelty and clinical potential of this approach.

###

TITLE: Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90

AUTHOR CONTACT:
Dario C. Altieri
University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Phone: (508) 856-5775; Fax: (508) 856-5792; E-mail: dario.altieri@umassmed.edu.

View the PDF of this article at: https://www.the-jci.org/article.php?id=37613

ACCOMPANYING COMMENTARY
TITLE: Shock the heat shock network

AUTHOR CONTACT:
Nesrin Özören
Bogaziçi University, Istanbul, Turkey.
Phone: 90-212-359-7558; Fax: 90-212-287-2468; E-mail: nesrin.ozoren@boun.edu.tr.

View the PDF of this article at: https://www.the-jci.org/article.php?id=38681


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.